{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Relay Therapeutics, Inc.
Relay Therapeutics Hits New 52-Week High of $7.50, Marking Major Milestone
Relay Therapeutics, Inc. achieved a new 52-week high of USD 7.50 on October 24, 2025, despite a 1-year performance decline of 8.9%. The company, with a market capitalization of approximately USD 700 million, remains loss-making and does not offer dividends, reflecting its microcap status.
Relay Therapeutics Hits Day High with 9.62% Surge in Stock Price
Relay Therapeutics, Inc. experienced a notable increase in stock performance on October 15, 2025, reaching an intraday high. The company has outperformed the S&P 500 over various periods, although it faces long-term challenges with significant declines in performance metrics and ongoing financial pressures.
Is Relay Therapeutics, Inc. technically bullish or bearish?
As of October 3, 2025, Relay Therapeutics, Inc. shows a bullish technical trend, supported by bullish MACD and moving averages, despite mixed signals from the weekly RSI and Dow Theory indicating a mildly bullish outlook.
Is Relay Therapeutics, Inc. technically bullish or bearish?
As of October 3, 2025, Relay Therapeutics, Inc. shows a bullish trend with strong performance against the S&P 500, but mixed signals from the RSI indicate caution despite recent gains.
Is Relay Therapeutics, Inc. technically bullish or bearish?
As of October 3, 2025, Relay Therapeutics, Inc. shows a bullish technical trend with strong weekly indicators, despite mixed signals from the RSI, and has outperformed the S&P 500 recently, though it has underperformed over the past year.
Is Relay Therapeutics, Inc. technically bullish or bearish?
As of September 12, 2025, Relay Therapeutics, Inc. shows a mildly bullish trend in the short term, supported by positive indicators like the weekly MACD and moving averages, despite mixed longer-term signals and a significant 1-year underperformance compared to the S&P 500.
Is Relay Therapeutics, Inc. overvalued or undervalued?
As of November 2, 2023, Relay Therapeutics, Inc. is considered risky due to its negative financial metrics, including a Price to Book Value of 0.80, an EV to EBITDA ratio of 0.34, a troubling -47.81% Return on Equity, and a one-year return of -39.97%, significantly underperforming compared to the S&P 500's 17.14% return.
Relay Therapeutics, Inc. Experiences Revision in Stock Evaluation Amid Mixed Performance Indicators
Relay Therapeutics, Inc. has experienced notable shifts in its technical indicators, with current trading reflecting a mixed performance. Despite recent fluctuations, the company has struggled significantly over the past year, with stock returns declining sharply compared to the S&P 500, indicating ongoing challenges in the market.
Is Relay Therapeutics, Inc. overvalued or undervalued?
As of November 2, 2023, Relay Therapeutics, Inc. is rated as "risky" and overvalued with key financial metrics indicating significant losses, including a negative ROE of -47.81%, and has underperformed the S&P 500 with a year-to-date return of -21.6%.
Is Relay Therapeutics, Inc. technically bullish or bearish?
As of June 20, 2025, the trend is mildly bearish due to daily moving averages, despite some mixed signals from weekly and monthly indicators, reflecting moderate bearish sentiment influenced by recent price declines.
Who are in the management team of Relay Therapeutics, Inc.?
As of March 2022, the management team of Relay Therapeutics, Inc. includes Dr. Sanjiv Patel as President and CEO, with Dr. Mark Murcko on the Board of Directors alongside independent directors Mr. Alexis Borisy, Dr. Linda Hill, Mr. Douglas Ingram, and Dr. Christoph Lengauer.
What does Relay Therapeutics, Inc. do?
Relay Therapeutics, Inc. is a clinical-stage precision medicines company focused on drug discovery in oncology. As of March 2025, it reported net sales of $8 million and a net loss of $77 million, with a market cap of $524.62 million.
How big is Relay Therapeutics, Inc.?
As of Jun 18, Relay Therapeutics, Inc. has a market capitalization of 524.62 million and reported net sales of 7.68 million with a net profit of -333.38 million over the latest four quarters. Shareholder's funds are 777.79 million, and total assets amount to 871.30 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
